RITUXAN

This brand name is authorized in United States. It is also authorized in Canada, Japan.

Active ingredients

The drug RITUXAN contains one active pharmaceutical ingredient (API):

1	Rituximab UNII 4F4X42SYQ6 - RITUXIMAB
	Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes. The antigen is expressed on >95% of all B cell non-Hodgkin’s lymphomas.
	Read more about Rituximab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RITUXAN Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FA01	Rituximab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FA CD20 (Clusters of Differentiation 20) inhibitors
Discover more medicines within L01FA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02241927, 02457350, 02473976
JP	医薬品医療機器総合機構	4291407A1035, 4291407A2031
US	FDA, National Drug Code	50242-051, 50242-053